IN
InterCure Ltd.
INCR · NASDAQ
$5.37 +1.90% (+$0.10)
1M -0.56%
Market Cap 195.3M ₪
P/E Ratio -
Div. Yield -
ROE 8.63%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
4/9Valuation
100 /100
Cheap P/B 0.49x
P/FCF 8.00x
P/S 0.72x
Growth
0 /100
Declining FCF growth 25.01%
Book val. growth 7.52%
Rev. growth 11.41%
Profitability
22 /100
Weak Net margin 13.22%
Op. margin 10.08%
FCF margin 9.04%
Quality
5 /100
Poor ROE 8.63%
ROA 5.17%
Asset turnover 0.39x
Debt
82 /100
Low Current ratio 1.48x
Debt/Equity 0.46x
Net debt/EBITDA N/A
Stability
40 /100
Moderate Rev. volatility 22.99%
EPS volatility 154.77%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about INCR
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Alexander Rabinovich
Employees
285
Headquarters
Herzliya